H-Leu-Ser-Lys-Leu-OH trifluoroacetate salt

Modify Date: 2024-02-25 18:19:21

H-Leu-Ser-Lys-Leu-OH trifluoroacetate salt Structure
H-Leu-Ser-Lys-Leu-OH trifluoroacetate salt structure
Common Name H-Leu-Ser-Lys-Leu-OH trifluoroacetate salt
CAS Number 162559-45-7 Molecular Weight 459.58000
Density N/A Boiling Point N/A
Molecular Formula C21H41N5O6 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of H-Leu-Ser-Lys-Leu-OH trifluoroacetate salt


H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis[1].

 Names

Name h-leu-ser-lys-leu-oh

  Biological Activity

Description H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis[1].
Related Catalog
Target

TGF-β1[1]

In Vitro H-Leu-Ser-Lys-Leu-OH (LSKL) 也可以阻断 TSP-1 对 TGF-β1 的激活,并降低 KRFK 肽对 TGF-β1 的激活[1]。
In Vivo H-Leu-Ser-Lys-Leu-OH (LSKL) (100 μg/0.5 mL; 腹腔注射; 每日给药,共 4 周; 并伴随着 DMN 的处理) 能够保护二甲基亚硝胺 (DMN) 处理 (10 mg/kg; 腹腔注射; 每周连续3天给药, 共 4 周) 导致的大鼠肝萎缩。H-Leu-Ser-Lys-Leu-OH 还可以预防肝损伤和纤维化的进展[1]。
References

[1]. Kondou H, et al. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J Hepatol. 2003 Nov;39(5):742-8.  

 Chemical & Physical Properties

Molecular Formula C21H41N5O6
Molecular Weight 459.58000
Exact Mass 459.30600
PSA 196.87000
LogP 1.63950

 Safety Information

WGK Germany 3